Orlando, FL-Most long-term survivors of metastatic renal cellcarcinoma do not achieve a response to cytokine treatment, according toresults of a pooled analysis by French researchers. Their findings suggesta lack of association between initial tumor regression on cytokine treatmentand long-term survival, except for the few patients who achieve completeregression.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.